Cartesian Therapeutics, Inc. (RNAC)
10.17
+0.13
(+1.29%)
USD |
NASDAQ |
Aug 24, 16:00
10.17
0.00 (0.00%)
After-Hours: 20:00
Cartesian Therapeutics EPS Diluted (Quarterly) : 0.4595 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.4595 |
| March 31, 2026 | -1.459 |
| December 31, 2025 | -3.559 |
| September 30, 2025 | -1.381 |
| June 30, 2025 | 0.6007 |
| March 31, 2025 | -0.6837 |
| September 30, 2024 | -1.126 |
| June 30, 2024 | 0.5412 |
| March 31, 2024 | -10.50 |
| December 31, 2023 | -41.56 |
| September 30, 2023 | -1.744 |
| June 30, 2023 | -2.226 |
| March 31, 2023 | -4.238 |
| December 31, 2022 | -1.502 |
| September 30, 2022 | -1.549 |
| June 30, 2022 | 1.738 |
| March 31, 2022 | 6.767 |
| December 31, 2021 | 2.960 |
| September 30, 2021 | -4.661 |
| June 30, 2021 | 1.130 |
| March 31, 2021 | -6.663 |
| Date | Value |
|---|---|
| December 31, 2020 | -4.296 |
| September 30, 2020 | -2.771 |
| June 30, 2020 | -7.464 |
| March 31, 2020 | -6.214 |
| December 31, 2019 | -8.536 |
| September 30, 2019 | -7.754 |
| June 30, 2019 | -10.96 |
| March 31, 2019 | -9.421 |
| December 31, 2018 | -19.58 |
| September 30, 2018 | -21.43 |
| June 30, 2018 | -25.22 |
| March 31, 2018 | -21.33 |
| December 31, 2017 | -26.40 |
| September 30, 2017 | -19.80 |
| June 30, 2017 | -25.50 |
| March 31, 2017 | -24.58 |
| December 31, 2016 | -23.10 |
| September 30, 2016 | -12.90 |
| June 30, 2016 | -82.50 |
| March 31, 2016 | -15.82 |
| March 31, 2015 | -11.73 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Allogene Therapeutics, Inc. | -0.1297 |
| Beam Therapeutics, Inc. | -1.176 |
| C4 Therapeutics, Inc. | -0.1808 |
| Kyverna Therapeutics, Inc. | -0.6292 |
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 13.72M |
| Total Expenses (Quarterly) | -13.72M |
| Enterprise Value | 217.83M |
| Earnings Yield | -58.40% |
| Normalized Earnings Yield | -39.89 |